Bisacodyl Suppository (10 mg)
For a patient failing oral senna and polyethylene glycol, bisacodyl suppository (10 mg) is the recommended rescue option, with onset of action within 30-60 minutes 1.
Rationale and Evidence
The 2023 AGA-ACG guideline explicitly addresses this clinical scenario 1. When oral laxatives fail to produce bowel movements, bisacodyl suppository provides rapid local stimulation:
- Onset of action: 30-60 minutes (compared to 6-12 hours for oral bisacodyl)
- Mechanism: Converted to the active metabolite BHPM by colonic mucosal enzymes, directly stimulating colonic peristalsis and secretion
- Positioning: Recommended specifically for short-term or rescue therapy when standard oral agents are insufficient
Clinical Implementation
Dosing: Use the 10 mg rectal suppository as a single dose. This is the standard suppository formulation studied and recommended 1.
Expected timeline: The patient should experience a bowel movement within 30-60 minutes of insertion. If no response occurs, reassess for potential obstruction or other complications before repeating.
Important Caveats
Contraindications 1:
- Ileus or intestinal obstruction
- Severe dehydration
- Acute inflammatory bowel conditions
Common adverse effects (from oral bisacodyl data, though suppository may differ) 1:
- Diarrhea (53% with oral 10 mg dose)
- Abdominal pain/cramping (25% with oral dose)
- Most side effects occur in the first week
Antibiotic interaction: Concurrent antibiotic use may decrease efficacy since antibiotics affect the colonic bacteria needed to produce the active metabolite 1.
Alternative Consideration
While the guideline prioritizes bisacodyl suppository, research suggests that polyethylene glycol-based bisacodyl suppositories work faster than traditional vegetable oil-based formulations 2, 3, 4. If available, PEG-based bisacodyl suppositories reduce total bowel care time by approximately 50% compared to hydrogenated vegetable oil-based versions, with time to flatus and defecation periods significantly shortened.
However, the guideline does not specify suppository base formulation, so either formulation is acceptable—just recognize that PEG-based versions may act more rapidly if the clinical situation is urgent.